<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00430144</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-214</org_study_id>
    <nct_id>NCT00430144</nct_id>
  </id_info>
  <brief_title>Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix</brief_title>
  <official_title>A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sokbom Kang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -list item one, The purpose of this study is to evaluate the overall response rate of
      belotecan (CKD-602) in recurrent or progressive carcinoma of uterine cervix
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  list item one, to evaluate toxicities of Belotecan

        -  list item two, to evaluate duration of primary response for responding patients

        -  list item three, to evaluate time to disease progression

        -  list item four, to evaluate progression free survival and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate of belotecan (CKD-602)</measure>
    <time_frame>1 week before the start of Cycle 4, 3 weeks later Cycle 6 or at discontinuation of study treatment, and then at least every 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>CKD-602</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belotecan(CKD-602)</intervention_name>
    <description>Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle</description>
    <arm_group_label>CKD-602</arm_group_label>
    <other_name>Camptobel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, patients with recurrent uterine cervical carcinoma who were
             unsuitable candidates for curative treatment with surgery and/or radiotherapy.

          -  One of the following histologic types

          -  Squamous cell carcinoma

          -  Adenocarcinoma

          -  Adenosquamous carcinoma

          -  Clinically measurable disease

          -  Performance status of 0, 1, 2 on the ECOG criteria

        Exclusion Criteria:

          -  Histology of neuroendocrine tumors

          -  Patient previously treated with topoisomerase-I inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sokbom Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>National cancer cencer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National cancer center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2007</study_first_submitted>
  <study_first_submitted_qc>January 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2007</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sokbom Kang</investigator_full_name>
    <investigator_title>director, gynecologic oncology research branch</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

